Trientine Hydrochloride (MAR-Trientine)

CADTH recommends that MAR-Trientine should be reimbursed by public drug plans for the treatment of patients with Wilson's disease if certain conditions are met. MAR-Trientine should only be covered to treat patients who have previously tried and demonstrated intolerance to d-penicillamine. MAR-Trientine should only be reimbursed if initiated by clinicians experienced in the management of Wilson’s disease and if the cost of MAR-Trientine is reduced.